Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen

Official title

A Study of Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen With Risk Factors:A Single-Arm, Multicenter Clinical Trial

Overview

The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in Ovarian and Cervical cancer patients at risk of platinum-containing chemotherapy with risk factors in febrile neutropenia (FN).

Detailed description

This study is a single-arm, multicenter clinical trial. A total of 83 patients will be enrolled, including 55 patients with primary epithelial ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) and 28 patients with primary or recurrent/metastatic cervical cancer in the first-line setting.

1\) Ovarian Cancer

Chemotherapy regimen (Paclitaxel + Carboplatin ± Bevacizumab):

Paclitaxel 175mg/m2, intravenous infusion over 3 hours, on day 1; followed by Carboplatin Area under the curve 5(AUC5), intravenous infusion over 1 hour, on day 1; Bevacizumab 7.5-15 mg/kg, on day 1, administered as intravenous infusion; repeated every 3 weeks.

(2) Cervical Cancer

Chemotherapy regimen (Paclitaxel + Carboplatin/Cisplatin ± Bevacizumab):

Paclitaxel 175mg/m2, intravenous infusion over 3 hours, on day 1; followed by Carboplatin AUC5, intravenous infusion over 1 hour, on day 1, or Cisplatin 50-80mg/m2, intravenous infusion over 1-3 hours, on day 1; Bevacizumab 7.5-15 mg/kg, on day 1, administered as intravenous infusion; repeated every 3 weeks.

Efbemalenograstim Alfa should be administered subcutaneously, 20mg per injection, within 24-48 hours after the completion of each chemotherapy cycle.

Interventions

• Drug Efbemalenograstim Alfa
  Efbemalenograstim Alfa is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Primary outcome measures

• Incidence of grade 3/4 neutropenia [Time frame: At the first of cycle 1 (each cycle is 21 days)]

Secondary outcome measures (4)

• The incidence rate of Grade 3/4 ANC reduction for each cycle [Time frame: in every treatment cycle( each cycle is 21 days)]
• The incidence rate of Grade ≥2 ANC reduction for each cycle [Time frame: in every treatment cycle( each cycle is 21 days)]
• The incidence rate of FN [Time frame: in every treatment cycle( each cycle is 21 days)]
• Adverse Events [Time frame: in every treatment cycle( each cycle is 21 days)]

Eligibility criteria

Inclusion criteria

• ≥ 18 years old and ≤ 70 years old.
• First-line epithelial ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) and first-line treatment or recurrent/metastatic cervical cancer.
• Planned to receive 3-6 cycles of paclitaxel + carboplatin/cisplatin ± bevacizumab therapy.
• Eastern Cooperative Oncology Group (ECOG) score < 2.
• Expected survival time > 3 months.
• Before enrollment, neutrophil count (ANC) ≥ 2.0 × 10\^9/L, hemoglobin (Hb) ≥ 90.0 g/L, and platelet (PLT) ≥ 80 × 10\^9/L.
• Associated with ≥ 1 self-factors increasing the risk of febrile neutropenia (FN): ① age > 65 years, receiving full-dose intensity chemotherapy; ② history of previous chemotherapy or radiotherapy; ③ persistent neutropenia; ④ tumor involvement of the bone marrow; ⑤ recent surgery and/or open wounds; ⑥ hepatic dysfunction (bilirubin > 2.0 mg•dL-1); ⑦ renal dysfunction (creatinine clearance rate < 50 mL•min-1); ⑧ history of previous FN occurrence; ⑨ concomitant malignant hematological or lymphatic system diseases; ⑩ chronic immunosuppression; ⑪ poor nutritional/physical status. Individualized judgment and decision-making based on the patient's specific condition are required in clinical practice.
• Left ventricular ejection fraction (LVEF) > 50%.
• Women who are not capable of reproduction, i.e., postmenopausal for at least 1 year or have undergone sterilization procedures (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy). Fertile patients agree to use appropriate contraceptive measures within 1 month before the start of the trial and up to 30 days after the end of the study, such as condoms, spermicidal condoms, foam, gel, diaphragm, intrauterine device (IUD), contraceptive pills (oral or injectable), etc.
• Willing to provide written informed consent and to compliant study procedure.
• The investigator determines that the patient can tolerate treatment with Efgbemalenograstim alfa.

Exclusion criteria

• Uncontrolled infection or systemic antibiotic therapy within 72 hours prior to chemotherapy.
• Pregnant or lactating women.
• History of bone marrow or stem cell transplantation.
• Concurrent malignancies other than primary ovarian or cervical cancer.
• Treatment with recombinant human granulocyte colony-stimulating factor within 6 weeks prior to enrollment.
• Psychiatric illness or brain metastases.
• Clinical, electrocardiographic, or other diagnostic evidence of acute congestive heart failure, cardiomyopathy, or myocardial infarction.
• Diseases associated with splenomegaly.
• Diagnosis of acute infection, chronic active hepatitis B within 1 year (unless known negative for hepatitis B virus antigen prior to enrollment), or hepatitis C.
• Allergy to recombinant human granulocyte colony-stimulating factor or excipients of the study drug, or allergy to rubber.
• Known positive serum reaction for human immunodeficiency virus (HIV) or AIDS.
• Active tuberculosis or recent history of contact with a tuberculosis patient unless negative on tuberculin skin test, or receiving treatment for tuberculosis, or suspected case on chest X-ray examination.
• Sickle cell anemia patients.
• Use of other investigational drugs within 1 month prior to enrollment.
• Patients who abuse alcohol or drugs, affecting their compliance with the study.
• The investigator believes that the patient has a disease or symptom that makes them unsuitable for participation in this study, or that the study drug may harm the patient's health or affect the assessment of adverse events.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

China · 6 centers

• Xiangya Hospital, Central South University, — Changsha
• Zhongda Hospital, School of Medicine, Southeast University — Nanjing
• Qilu Hospital of Shandong University — Jinan
• Qingdao Central Hospital, The Second Affiliated Hospital of Medical College of Qingdao Uni — Qingdao
• Shanxi Provincial Cancer Hospital — Taiyuan
• Zhejiang Cancer Hospital — Hangzhou

Identifiers

NCT: NCT06251947 · Guard-05 · Guard-05

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗